Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The DUTRENEO Trial: A Prospective Study to Individualize the Approach With DUrvalumab (MEDI4736) and TREmelimumab in NEOadjuvant Bladder Cancer Patients.

NCT03472274 is registered in ClinicalTrials.gov with Fundacion CRIS de Investigación para Vencer el Cáncer as lead sponsor.

NCT NCT03472274
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03472274 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The DUTRENEO Trial: A Prospective Study to Individualize the Approach With DUrvalumab (MEDI4736) and TREmelimumab in NEOadjuvant Bladder Cancer Patients.
Lead sponsor
Fundacion CRIS de Investigación para Vencer el Cáncer
Phase
Phase 2
Overall status
Completed
Start date
October 25, 2018
Completion date
April 12, 2023
Enrollment
101 (actual)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

bladder cancer